For patients with heart failure with preserved ejection fraction, tirzepatide yields a reduced risk for a composite of death from cardiovascular causes or worsening heart failure.

BACKGROUND: Heart failure with preserved ejection fraction (HFpEF) is a major health concern. Pathological stimuli and interactions between cardiac fibroblasts (CFs) and other cell types may lead to ...

From 2021 to 2023, there was an increase in prescription rates of a sodium-glucose cotransporter-2 inhibitor (SGLT2i) for patients with heart failure and a left ventricular ejection fraction (LVEF) ...

On November 16, at the 100th American Heart Association (AHA) Scientific Sessions ... in patients with obesity and heart failure with preserved ejection fraction (HFpEF) on the major heart failure ...

Heart failure is broken down into big two categories based on the ejection fraction (EF) of the heart, which is the percentage of blood that the left ventricle squeezes out during each beat.

AHA 2024 REALIZE ... get patients with heart failure on the right drugs at the right doses. Commentary, November 26, 2024 ESC 2024 Can You Deprescribe After Ejection Fraction Improvement?

Lower risk for composite of death from cardiovascular causes or worsening heart failure seen with tirzepatide versus placebo. (HealthDay News) — For patients with heart failure with preserved ...

From 2021 to 2023, there was an increase in prescription rates of a sodium-glucose cotransporter-2 inhibitor (SGLT2i) for ...